Regencell Bioscience (NASDAQ:RGC) Stock Price Up 6.7% – Here’s What Happened

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares rose 6.7% during mid-day trading on Wednesday . The company traded as high as $5.86 and last traded at $5.8710. Approximately 58,345 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 296,605 shares. The stock had previously closed at $5.50.

Analyst Ratings Changes

RGC has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a report on Wednesday, June 24th. Wall Street Zen cut shares of Regencell Bioscience from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Regencell Bioscience has a consensus rating of “Sell”.

Regencell Bioscience Price Performance

The firm has a 50-day moving average price of $5.80 and a 200 day moving average price of $18.66.

Institutional Investors Weigh In On Regencell Bioscience

A number of hedge funds and other institutional investors have recently modified their holdings of RGC. Seven Fleet Capital Management LP bought a new stake in shares of Regencell Bioscience in the fourth quarter valued at about $92,000. Amundi acquired a new stake in Regencell Bioscience in the 1st quarter worth about $219,000. Hudson Bay Capital Management LP acquired a new position in shares of Regencell Bioscience during the 4th quarter worth approximately $275,000. Bank of America Corp DE increased its holdings in shares of Regencell Bioscience by 59,113.8% during the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock worth $437,000 after purchasing an additional 17,143 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of Regencell Bioscience during the third quarter worth approximately $598,000. Institutional investors and hedge funds own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.